FY2024 EPS Estimates for Spectral AI Increased by Analyst

Spectral AI, Inc. (NASDAQ:MDAI) – Analysts at Northland Capmk increased their FY2024 earnings per share estimates for Spectral AI in a research report issued on Tuesday, December 3rd. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings per share of ($0.48) for the year, up from their prior forecast of ($0.67). Northland Capmk currently has a “Strong-Buy” rating on the stock. The consensus estimate for Spectral AI’s current full-year earnings is ($0.54) per share. Northland Capmk also issued estimates for Spectral AI’s Q4 2024 earnings at ($0.10) EPS.

MDAI has been the subject of a number of other research reports. Northland Securities initiated coverage on shares of Spectral AI in a report on Monday, August 12th. They set an “outperform” rating and a $6.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $3.50 price objective on shares of Spectral AI in a research note on Tuesday, August 13th.

Spectral AI Price Performance

NASDAQ MDAI opened at $2.03 on Thursday. The company has a fifty day moving average price of $1.37 and a 200-day moving average price of $1.51. Spectral AI has a 1 year low of $0.82 and a 1 year high of $3.72. The firm has a market cap of $37.74 million, a price-to-earnings ratio of -3.12 and a beta of 0.64.

Hedge Funds Weigh In On Spectral AI

An institutional investor recently bought a new position in Spectral AI stock. Virtu Financial LLC bought a new position in shares of Spectral AI, Inc. (NASDAQ:MDAI) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 17,830 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned 0.10% of Spectral AI at the end of the most recent quarter. 67.08% of the stock is currently owned by institutional investors and hedge funds.

About Spectral AI

Spectral AI, Inc, an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers.